Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
View Patent ↗This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
1. A pharmaceutically acceptable salt of a compound selected from the group consisting of:
N-(5-tert-butyl-2-methoxy phenyl)-N′-(4-(4-methoxy-3-(N-methylcarbamoyl)phenoxy)phenyl)urea,
N-(2-methoxy-5-(trifluoromethyl)phenyl)-N′-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea,
N-(4-chloro-3-(trifluoromethyl)phenyl)-N′-(4-(2-carbamoyl-4-pyridyloxy)phenyl)urea,
N-(4-chloro-3-(trifluoromethyl)phenyl)-N′-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea;
N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-N′-(3-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea and their pharmaceutically acceptable salts.
2. A pharmaceutically acceptable salt of the compound
N-(5-tert-butyl-2-methoxy phenyl)-N′-(4-(4-methoxy-3-(N-methylcarbamoyl)phenoxy)phenyl)urea.
3. A pharmaceutically acceptable salt of claim 2 selected from the group consisting of
a) basic salts of organic acids and inorganic acids selected from the group consisting of hydrochloric acid, hydrobromic acid, sulpheric acid, phosphoric acid, methanesulphonic acid, triflurosulphonic acid, benzenesulfonic acid, p-tolune sulphonic acid(tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicyclic acid, phenylacetic acid, and mandelic acid; and
b) acid salts of organic and inorganic bases containing cations selected from the group consisting of alkaline cations, alkaline earth cations, the ammonium cation, aliphatic substituted ammonium cations and aromatic substituted ammonium cations.
4. A pharmaceutically acceptable salt of the compound
N-(2-methoxy-5-(trifluoromethyl)phenyl)-N′-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea.
5. A pharmaceutically acceptable salt of a compound which is:
N-(2-methoxy-5-(trifluoromethyl) phenyl)-N'-(4(2-(N-methylcarbamoyl)-4-pyridyloxy) phenyl) urea of the formula:
N-(4-chloro-3-(trifluoromethyl) phenyl)-N'-(4(2-(N-carbamoyl)-4-pyridyloxy) phenyl) urea of the formula:
N-(4-chloro-3-(trifluoromethyl) phenyl)-N'-(4(2-(N-methylcarbamoyl)-4-pyridyloxy) phenyl) urea of the formula:
N-(2-methoxy-4-chloro-5-(trifloromethyl) phenyl)-N'-(3(2-(N-methylcarbamoyl)-4-pyridyloxy) phenyl) urea of the formula:
6. A pharmaceutically acceptable salt of the compound
N-(4-chloro-3-(triflouromethyl)phenyl)-N′-(2carbamoyl-4-pyridyloxy)phenyl)urea. -pyridyloxy)phenyl)urea.
7. A pharmaceutically acceptable salt which is the tosylate salt of
N-(2-methoxy-5-(trifluoromethyl) phenyl)-N'-(4(2-(N-methylcarbamoyl)-4-pyridyloxy) phenyl) urea of the formula:
N-(4-chloro-3-(trifluoromethyl) phenyl)-N'-(4(2-(N-carbamoyl-4-pyridyloxy) phenyl) urea of the formula:
N-(4-chloro-3-(trifluoromethyl) phenyl)-N'-(4(2-(N-methylcarbamoyl)-4-pyridyloxy) phenyl) urea of the formula:
N-(2-methoxy-4-chloro-5-(trifloromethyl) phenyl)-N'-(3(2-(N-methylcarbamoyl)-4-pyridyloxy) phenyl) urea of the formula:
8. A pharmaceutically acceptable salt of a compound which is:
N-(4-chloro-3-(trifluoromethyl) phenyl)-N'-(4(2-(N-carbamoyl-4-pyridyloxy) phenyl) urea of the formula:
N-(4-chloro-3-(trifluoromethyl) phenyl)-N'-(4(2-(N-methylcarbamoyl)-4-pyridyloxy) phenyl) urea of the formula:
N-(2-methoxy-4-chloro-5-(trifloromethyl) phenyl)-N'-(3(2-(N-methylcarbamoyl)-4-pyridyloxy) phenyl) urea of the formula:
9. A pharmaceutically acceptable salt of claim 8 selected from the group consisting of
a) basic salts of organic acids and inorganic acids selected from the group consisting of hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, trifluorosulphonic acid, benzenesulfonic acid, p-toluene sulphonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, and mandelic acid; and
b) acid salts of organic and inorganic bases containing cations selected from the group consisting of alkaline cations, alkaline earth cations, the ammonium cation, aliphatic substituted ammonium cations and aromatic substituted ammonium cations.
10. A pharmaceutically acceptable salt which is the tosylate salt of
N-(4-chloro-3-(trifluoromethyl) phenyl)-N'-(4(2-(N-carbamoyl-4-pyridyloxy) phenyl) urea of the formula:
N-(4-chloro-3-(trifluoromethyl) phenyl)-N'-(4(2-(N-methylcarbamoyl)-4-pyridyloxy) phenyl) urea of the formula:
N-(2-methoxy-4-chloro-5-(trifloromethyl) phenyl)-N'-(3(2-(N-methylcarbamoyl)-4-pyridyloxy) phenyl) urea of the formula:
11. A pharmaceutically acceptable salt of claim 10 selected from the group consisting of
a) basic salts of organic acids and inorganic acids selected from the group consisting of hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, trifluorosulphonic acid, benzenesulfonic acid, p-toluene sulphonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, and mandelic acid; and
b) acid salts of organic and inorganic bases containing cations selected from the group consisting of alkaline cations, alkaline earth cations, the ammonium cation, aliphatic substituted ammonium cations and aromatic substituted ammonium cations.
12. A method for the treatment of a cancerous cell growth mediated by RAF kinase comprising administering a pharmaceutically acceptable salt of a compound selected from the group consisting of:
N-(5-tert-butyl-2-methoxy phenyl)-N′-(4-(4-methoxy-3-(N-methylcarbamoyl)phenoxy)phenyl)urea,
N-(2-methoxy-5-(trifluoromethyl)phenyl)-N′-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea,
N-(4-chloro-3-(trifluoromethyl)phenyl)-N′-(4-(2-carbamoyl-4-pyridyloxy)phenyl)urea,
N-(4-chloro-3-(trifluoromethyl)phenyl)-N′-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea;
N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-N′-(3-(2-(N-methylcarbamoyl)4-pyridyloxy)phenyl)urea.
13. A method for the treatment of a cancerous cell growth as in claim 12 mediated by RAF kinase comprising administering a pharmaceutically acceptable salt of
N-(5-tert-butyl-2-methoxy phenyl)-N′-(4-(4-methoxy-3-(N-methylcarbamoyl)phenoxy)phenyl)urea.
14. A method for the treatment of a cancerous cell growth as in claim 12 mediated by RAF kinase comprising administering a pharmaceutically acceptable salt of
N-(2-methoxy-5-(trifluoromethyl)phenyl)-N′-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea.
15. A method for the treatment of a cancerous cell growth as in claim 12 mediated by RAF kinase comprising administering a pharmaceutically acceptable salt of
N(4-chloro-3-(trifluoromethyl)phenyl)-N′-(4-(2-carbamoyl-4-pyridyloxy)phenyl)urea.
16. A method for the treatment of a cancerous cell growth as in claim 12 mediated by RAF kinase comprising administering a pharmaceutically acceptable salt of
N-(4-chloro-3-(trifluoromethyl)phenyl)-N′-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea.
17. A method for the treatment of a cancerous cell growth as in claim 12 mediated by RAF kinase comprising administering a pharmaceutically acceptable salt of
N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)N′-(3-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea.
18. A method as in claim 12 for the treatment of solid cancers.
19. A method as in claim 12 for the treatment of carcinomas, myleoid disorders or adenomas.
20. A method as in claim 13 for the treatment of carcinomas, myleoid disorders or adenomas.
21. A method as in claim 14 for the treatment of carcinomas, myleoid disorders or adenomas.
22. A method as in claim 15 for the treatment of carcinomas, myleoid disorders or adenomas.
23. A method as in claim 16 for the treatment of carcinomas, myleoid disorders or adenomas.
24. A method as in claim 17 for the treatment of carcinomas, myleoid disorders or adenomas.
25. A method as in claim 12 for the treatment of carcinoma of the lung, pancreas, thyroid, bladder or colon.
26. A method as in claim 13 for the treatment of carcinoma of the lung, pancreas, thyroid, bladder or colon.
27. A method as in claim 14 for the treatment of carcinoma of the lung, pancreas, thyroid, bladder or colon.
28. A method as in claim 15 for the treatment of carcinoma of the lung, pancreas, thyroid, bladder or colon.
29. A method as in claim 16 for the treatment of carcinoma of the lung, pancreas, thyroid, bladder or colon.
30. A method as in claim 17 for the treatment of carcinoma of the lung, pancreas, thyroid, bladder or colon.
31. A method as in claim 12 for the treatment of myeloid leukemia or villous colon adenomas.
32. A method as in claim 13 for the treatment of myeloid leukemia or villous colon adenomas.
33. A method as in claim 14 for the treatment of myeloid leukemia or villous colon adenomas.
34. A method as in claim 15 for the treatment of myeloid leukemia or villous colon adenomas.
35. A method as in claim 16 for the treatment of myeloid leukemia or villous colon adenomas.
36. A method as in claim 17 for the treatment of myeloid leukemia or villous colon adenomas.
37. A method as in claim 12 wherein the pharmaceutically acceptable salt administered is selected from the group of salts consisting of
a) basic salts of organic acids and inorganic acids selected from the group consisting of hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, trifluorosulphonic acid, benzenesulfonic acid, p-toluene sulphonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, and mandelic acid; and
b) acid salts of organic and inorganic bases containing cations selected from the group consisting of alkaline cations, alkaline earth cations, the ammonium cation, aliphatic substituted ammonium cations and aromatic substituted ammonium cations.
38. A method as in claim 13 where the pharmaceutical acceptable salt administered is the tosylate salt of
N-(5-tert-butyl-2-methoxy phenyl)-N′-(4-(4-methoxy-3-(N-methylcarbamoyl)phenoxy)phenyl)urea.
39. A method as in claim 14 where the pharmaceutical acceptable salt administered is the tosylate salt of
N-(2-methoxy-5-(trifluoromethyl)phenyl)-N′-(4-(2-(N-methylcarbarmoyl)-4-pyridyloxy)phenyl)urea.
40. A method as in claim 15 where the pharmaceutical acceptable salt administered is the tosylate salt of
N-(4-chloro-3-(trifluromethyl)phenyl)-N′-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea.
41. A method as in claim 16 where the pharmaceutical acceptable salt administered is the tosylate salt of
N-(4-chloro-3-(trifluoromethyl)phenyl)-N′-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea.
42. A method as in claim 17 where the pharmaceutical acceptable salt administered is the tosylate salt of
N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-N′-(3-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea.
43. A pharmaceutical acceptable salt as in claim 2 which is the tosylate salt of
N-(5-tert-butyl-2-methoxy phenyl)-N′-(4-(4-methoxy-3-(N-methylcarbamoyl)phenoxy)phenyl)urea.
44. A pharmaceutical acceptable salt as in claim 4 which is the tosylate salt of
N-(2-methoxy-5-(trifluoromethyl)phenyl)-N′-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea.
45. A pharmaceutical acceptable salt as in claim 6 which is the tosylate salt of
N-(4-chloro-3-(trifluoromethyl)phenyl)-N′-(4-(2-carbamoyl-4-pyridyloxy)phenyl)urea.
46. A pharmaceutical acceptable salt as in claim 8 which is the tosylate salt of
N-(4-chloro-3-(trifluoromethyl)phenyl)-N′-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea.
47. A pharmaceutical acceptable salt as in claim 10 which is the tosylate salt of
N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-N′-(3-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea.